TY - JOUR T1 - Statistical testing between counter measure vs herd immunity in the case of COVID-19 outbreak in Wuhan and Japan JF - medRxiv DO - 10.1101/2020.04.26.20081315 SP - 2020.04.26.20081315 AU - Junko Kurita AU - Tamie Sugawara AU - Yasushi Ohkusa Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/09/2020.04.26.20081315.abstract N2 - Background The COVID-19 outbreak has shown two inconsistent phenomena: its reproduction number is almost two; and it shows earlier and lower peaks for new cases and the total number of patients.Object To resolve this inconsistency, we constructed a mathematical model to explain these phenomena under the two hypotheses that effective counter measure and herd immunity.Method To outbreak data from Wuhan, China and Japan, we applied a susceptible–infected–recovery model with the proportion of asymptomatic patients among infected people (q) as a key parameter for estimation, along with the basic reproduction number (R0) and effective reproduction number under counter measure (Re).Results The first outbreak peak was recorded in Japan on April 3 for those infected on March 29. R0, Re and q were estimated respectively as 3.78, 3.44 and 99.32% in Wuhan. In Japan, these were estimated around the peak as 2.97, 2.78 and 99.99%. In both area, Reproduction numbers before and after counter measure initiation were not significantly difference.Discussion and Conclusion By introducing a very high proportion of asymptomatic cases, the two inconsistent phenomena might be resolved. These phenomena can be explained better by herd immunity was supported than counter measure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases. https://www.mhlw.go.jp/stf/newpage_10723.html ER -